Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants

Coronaviruses have been the causative agent of three epidemics and pandemics in the past two decades, including the ongoing COVID-19 pandemic. A broadly-neutralizing coronavirus therapeutic is desirable not only to prevent and treat COVID-19, but also to provide protection for high-risk populations...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollingsworth, Scott A., Noland, Cameron L., Vroom, Karin, Saha, Anasuya, Sam, Miranda, Gao, Qinshan, Zhou, Haihong, Grandy, David U., Singh, Sujata, Wen, Zhiyun, Warren, Christopher, Ma, Xiaohong Shirley, Malashock, Daniel, Galli, Jennifer, Go, Gwenny, Eddins, Michael, Mayhood, Todd, Sathiyamoorthy, Karthik, Fridman, Arthur, Raoufi, Fahimeh, Gomez-Llorente, Yacob, Patridge, Andrea, Tang, Yinyan, Chen, Shi-Juan, Bailly, Marc, Ji, Chengjie, Kingsley, Laura J., Cheng, Alan C., Geierstanger, Bernhard H., Gorman, Daniel M., Zhang, Lan, Pande, Kalyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444775/
https://www.ncbi.nlm.nih.gov/pubmed/37608223
http://dx.doi.org/10.1038/s41598-023-40919-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444775/
https://www.ncbi.nlm.nih.gov/pubmed/37608223
http://dx.doi.org/10.1038/s41598-023-40919-7

Ejemplares similares